{"id":12531,"date":"2021-06-29T16:59:45","date_gmt":"2021-06-29T11:29:45","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=12531"},"modified":"2021-07-24T12:58:28","modified_gmt":"2021-07-24T07:28:28","slug":"pharma-happenings-for-intellia-innovent-synaffix-lilly-polyphor","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-intellia-innovent-synaffix-lilly-polyphor","title":{"rendered":"Intellia&#8217;s Quest with CRISPR; Innovent, Synaffix ADC Tech Deal; Lilly&#8217;s Diabetes Blockbuster Tirzepatide; Polyphor\u2019s Bleak Future"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a2fb7080d80c\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a2fb7080d80c\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-intellia-innovent-synaffix-lilly-polyphor\/#A_New_Dawn_for_CRISPR_Intellia_Edits_Cells_Inside_the_Body\" >A New Dawn for CRISPR, Intellia Edits Cells Inside the Body<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-intellia-innovent-synaffix-lilly-polyphor\/#Innovent_Synaffix_Signs_Up_an_ADC-Tech_License_Deal\" >Innovent, Synaffix Signs Up an ADC-Tech License Deal<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-intellia-innovent-synaffix-lilly-polyphor\/#Eli_Lillys_Tirzepatide_Shows_Blockbuster_Potential_in_Diabetes\" >Eli Lilly&#8217;s Tirzepatide Shows Blockbuster Potential in Diabetes&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-intellia-innovent-synaffix-lilly-polyphor\/#Polyphors_Drug_Flops_in_Breast_Cancer_Puts_the_Firm_in_Tight_Spot\" >Polyphor\u2019s Drug Flops in Breast Cancer, Puts the Firm in Tight Spot&nbsp;<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\" id=\"h-a-new-dawn-for-crispr-intellia-edits-cells-inside-the-body\"><span class=\"ez-toc-section\" id=\"A_New_Dawn_for_CRISPR_Intellia_Edits_Cells_Inside_the_Body\"><\/span><strong>A New Dawn for CRISPR, Intellia Edits Cells Inside the Body<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Intellia Therapeutics, along with its partner Regeneron Pharmaceuticals, recently announced its successful attempt in editing the cells inside the body leveraging the CRISPR technique. The world\u2019s first-ever trial that has their DNA edited through an in vivo CRISPR\/Cas9 therapy brought good news for everyone as the trials managed to present improvements in a rare inherited liver disorder.<\/p>\n\n\n\n<p>The robust efficacy data was coupled with an encouraging safety profile with no serious adverse events as observed in the first six patients as of day 28. The treatment aims to repair a gene responsible for <a href=\"https:\/\/www.delveinsight.com\/report-store\/transthyretin-amyloid-cardiomyopathy-market?utm_source=blog&amp;utm_medium=article&amp;utm_campaign=v\" target=\"_blank\" rel=\"noreferrer noopener\">transthyretin amyloidosis<\/a>, or ATTR. As per DelveInsight\u2019s ATTR epidemiological analysis, In 2017, the total diagnosed prevalent population in the 7MM was 19,344, which is further expected to rise.\u00a0<\/p>\n\n\n\n<p>Although, there exists approved medications and drugs such as <strong>Onpattro <\/strong>(Patisiran), <strong>Tegsedi <\/strong>(Inotersen), and symptomatic therapies such as analgesics for the treatment of transthyretin amyloidosis, and it is expected to act as a hindrance for the firm while vying for the market share. However, gene-editing provides a one-time treatment option meant to offer permanent solutions like halting, or reversing the disease&#8217;s downward course, which will surely provide Innovent a leg-up over other pharma players in the market.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-innovent-synaffix-signs-up-an-adc-tech-license-deal\"><span class=\"ez-toc-section\" id=\"Innovent_Synaffix_Signs_Up_an_ADC-Tech_License_Deal\"><\/span><strong>Innovent, Synaffix Signs Up an ADC-Tech License Deal<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Innovent Biologics has entered into a non-exclusive, target-specific license agreement with Synaffix to leverage its <a href=\"https:\/\/www.delveinsight.com\/asco-conference\/article\/antibody-drug-conjugates-market?utm_source=blog&amp;utm_medium=article&amp;utm_campaign=v\" target=\"_blank\" rel=\"noreferrer noopener\">Antibody-drug conjugates (ADCs) technology<\/a>.<\/p>\n\n\n\n<p>Going by the agreement, Synaffix is eligible for upfront payment, potential milestones payments, along with royalties on the basis of potential future commercial sales of the ADC product in return for all the necessary proprietary ADC technologies including GlycoConnect, HydraSpace, and one of its toxSYN linker-payloads.&nbsp;<\/p>\n\n\n\n<p>While Innovent will receive the rights to leverage the ADC technology for one therapeutic molecule and will be solely responsible for R&amp;D, development and manufacturing of the product as well as its commercialization, Synaffix will help Innovent with the procurement of the parts and products specific to its ADC technology.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-eli-lilly-s-tirzepatide-shows-blockbuster-potential-in-diabetes\"><span class=\"ez-toc-section\" id=\"Eli_Lillys_Tirzepatide_Shows_Blockbuster_Potential_in_Diabetes\"><\/span><strong>Eli Lilly&#8217;s Tirzepatide Shows Blockbuster Potential in Diabetes&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Eli Lilly\u2019s Tirzepatide continues to steal the attention with its potential in treating Diabetes, outwinning several drugs in clinical trials.&nbsp;<\/p>\n\n\n\n<p>Lilly\u2019s investigation drug, Tirzepatide, is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, which managed to reduce hemoglobin A1C (HbA1c) levels in people with type 2 <a href=\"https:\/\/www.delveinsight.com\/blog\/diabetes-types-risk-factors-and-treatment-options\/?utm_source=blog&amp;utm_medium=article&amp;utm_campaign=v\" target=\"_blank\" rel=\"noreferrer noopener\">Diabetes<\/a> while supporting weight loss.\u00a0<\/p>\n\n\n\n<p>It also led to improvements in the change in fasting serum glucose from baseline and improvements in the change in two-hour post-meal glucose values from baseline (<strong>SURPASS-1<\/strong>). Based on positive results, the company plans to file for regulatory approval by the end of this year.&nbsp;<\/p>\n\n\n\n<p>The company is also investigating the drug in <a href=\"https:\/\/www.delveinsight.com\/report-store\/nonalcoholic-steatohepatitis-nash-market?utm_source=blog&amp;utm_medium=article&amp;utm_campaign=v\" target=\"_blank\" rel=\"noreferrer noopener\">non-alcoholic steatohepatitis<\/a> (NASH) and heart failure with preserved ejection fraction (HFpEF).\u00a0<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-polyphor-s-drug-flops-in-breast-cancer-puts-the-firm-in-tight-spot\"><span class=\"ez-toc-section\" id=\"Polyphors_Drug_Flops_in_Breast_Cancer_Puts_the_Firm_in_Tight_Spot\"><\/span><strong>Polyphor\u2019s Drug Flops in Breast Cancer, Puts the Firm in Tight Spot&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Swiss pharmaceutical company, Polyphor, saw its share price crashing after its therapy intended to cure Breast cancer failed.&nbsp;<\/p>\n\n\n\n<p>The announcement follows the results from a global phase III trial (<strong>FORTRESS) <\/strong>that evaluated balixafortide (POL6326) and eribulin to treat patients who have <a href=\"https:\/\/www.delveinsight.com\/report-store\/hr-positive-her-negative-market?utm_source=blog&amp;utm_medium=article&amp;utm_campaign=v\" target=\"_blank\" rel=\"noreferrer noopener\">HER2 negative, locally recurrent, or metastatic breast cancer<\/a>. The cocktail therapy failed to produce any such significant difference in the objective response rate (ORR) compared to using just eribulin, even after six months of observations.<\/p>\n\n\n\n<p>The unexpected failure has very much jeopardized the existence of the company, which was solely relying on its cancer therapy for potential future revenue. Although the firm owns a novel class antibiotic that targets lung infections, the sales projections have been poor. Polyphor now plans to further discuss with experts the due course of the drug after the failure of FORTRESS.&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>A New Dawn for CRISPR, Intellia Edits Cells Inside the Body Intellia Therapeutics, along with its partner Regeneron Pharmaceuticals, recently announced its successful attempt in editing the cells inside the body leveraging the CRISPR technique. The world\u2019s first-ever trial that has their DNA edited through an in vivo CRISPR\/Cas9 therapy brought good news for everyone [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":12533,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[78,127,812,228,17095,17093,1469,1470,17094],"industry":[17225],"therapeutic_areas":[17242,17235,17240],"class_list":["post-12531","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-antibody-drug-conjugates","tag-breast-cancer","tag-diabetes","tag-eli-lilly","tag-her2-negative-breast-cancer","tag-intellia-therapeutics","tag-nash","tag-nonalcoholic-steatohepatitis","tag-polyphor","industry-pharmaceutical","therapeutic_areas-cardiovascular-diseases","therapeutic_areas-cell-and-gene-therapy","therapeutic_areas-endocrinology-and-metabolic-disorders"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Intellia&#039;s Quest with CRISPR; Lilly&#039;s Diabetes Blockbuster Tirzepatide<\/title>\n<meta name=\"description\" content=\"Intellia&#039;s Quest with CRISPR; Innovent, Synaffix ADC Tech Deal; Lilly&#039;s Diabetes Blockbuster Tirzepatide; Polyphor\u2019s Bleak Future\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-intellia-innovent-synaffix-lilly-polyphor\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Intellia&#039;s Quest with CRISPR; Lilly&#039;s Diabetes Blockbuster Tirzepatide\" \/>\n<meta property=\"og:description\" content=\"Intellia&#039;s Quest with CRISPR; Innovent, Synaffix ADC Tech Deal; Lilly&#039;s Diabetes Blockbuster Tirzepatide; Polyphor\u2019s Bleak Future\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-intellia-innovent-synaffix-lilly-polyphor\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2021-06-29T11:29:45+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:28:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/06\/29165444\/News-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Intellia's Quest with CRISPR; Lilly's Diabetes Blockbuster Tirzepatide","description":"Intellia's Quest with CRISPR; Innovent, Synaffix ADC Tech Deal; Lilly's Diabetes Blockbuster Tirzepatide; Polyphor\u2019s Bleak Future","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-intellia-innovent-synaffix-lilly-polyphor","og_locale":"en_US","og_type":"article","og_title":"Intellia's Quest with CRISPR; Lilly's Diabetes Blockbuster Tirzepatide","og_description":"Intellia's Quest with CRISPR; Innovent, Synaffix ADC Tech Deal; Lilly's Diabetes Blockbuster Tirzepatide; Polyphor\u2019s Bleak Future","og_url":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-intellia-innovent-synaffix-lilly-polyphor","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2021-06-29T11:29:45+00:00","article_modified_time":"2021-07-24T07:28:28+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/06\/29165444\/News-1.jpg","type":"image\/jpeg"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-intellia-innovent-synaffix-lilly-polyphor","url":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-intellia-innovent-synaffix-lilly-polyphor","name":"Intellia's Quest with CRISPR; Lilly's Diabetes Blockbuster Tirzepatide","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-intellia-innovent-synaffix-lilly-polyphor#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-intellia-innovent-synaffix-lilly-polyphor#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/06\/29165444\/News-1.jpg","datePublished":"2021-06-29T11:29:45+00:00","dateModified":"2021-07-24T07:28:28+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"Intellia's Quest with CRISPR; Innovent, Synaffix ADC Tech Deal; Lilly's Diabetes Blockbuster Tirzepatide; Polyphor\u2019s Bleak Future","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-intellia-innovent-synaffix-lilly-polyphor"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-intellia-innovent-synaffix-lilly-polyphor#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/06\/29165444\/News-1.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/06\/29165444\/News-1.jpg","width":772,"height":482,"caption":"Intellia's Quest with CRISPR; Innovent, Synaffix ADC Tech Deal; Lilly's Diabetes Blockbuster Tirzepatide; Polyphor\u2019s Bleak Future"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/06\/29165444\/News-1-300x187.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Antibody-Drug Conjugates<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Breast Cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Diabetes<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Eli Lilly<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">HER2 Negative Breast Cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Intellia Therapeutics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">NASH<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Nonalcoholic Steatohepatitis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Polyphor<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Antibody-Drug Conjugates<\/span>","<span class=\"advgb-post-tax-term\">Breast Cancer<\/span>","<span class=\"advgb-post-tax-term\">Diabetes<\/span>","<span class=\"advgb-post-tax-term\">Eli Lilly<\/span>","<span class=\"advgb-post-tax-term\">HER2 Negative Breast Cancer<\/span>","<span class=\"advgb-post-tax-term\">Intellia Therapeutics<\/span>","<span class=\"advgb-post-tax-term\">NASH<\/span>","<span class=\"advgb-post-tax-term\">Nonalcoholic Steatohepatitis<\/span>","<span class=\"advgb-post-tax-term\">Polyphor<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 5 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Jun 29, 2021","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Jun 29, 2021 4:59 pm","modified":"Updated on Jul 24, 2021 12:58 pm"},"featured_img_caption":"Intellia's Quest with CRISPR; Innovent, Synaffix ADC Tech Deal; Lilly's Diabetes Blockbuster Tirzepatide; Polyphor\u2019s Bleak Future ","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/12531","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=12531"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/12531\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/12533"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=12531"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=12531"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=12531"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=12531"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=12531"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}